Safety in numbers--monitoring risk in approved drugs.
暂无分享,去创建一个
Dr. Susan Okie reports on how drug-policy experts, lawmakers, consumer advocates, and federal officials are all calling for better ways of monitoring drug safety. The urgency of this effort is clea...
[1] B. Psaty,et al. Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis , 2004 .
[2] R. Stafford,et al. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. , 2005, Archives of internal medicine.